Cargando…
Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development
Chikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are not highly efficient for outbreak containment, vaccines are essential to reduce the burden of disease. Although no licensed vaccine against...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336248/ https://www.ncbi.nlm.nih.gov/pubmed/30653504 http://dx.doi.org/10.1371/journal.pntd.0006919 |
_version_ | 1783388022972088320 |
---|---|
author | Rezza, Giovanni Weaver, Scott C. |
author_facet | Rezza, Giovanni Weaver, Scott C. |
author_sort | Rezza, Giovanni |
collection | PubMed |
description | Chikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are not highly efficient for outbreak containment, vaccines are essential to reduce the burden of disease. Although no licensed vaccine against CHIKF is yet available, many highly promising candidates are undergoing preclinical studies, and a few of them have been tested in human trials of phase 1 or 2. Here, we review recent findings regarding the need for a CHIKF vaccine and provide an update on vaccines nearing or having entered clinical trials. We also address needs to tackle bottlenecks to vaccine development—including scientific and financial barriers—and to accelerate the development of vaccines; several actions should be taken: (i) design efficacy trials to be conducted during the course of outbreaks; (ii) evaluate the opportunity for adopting the “animal rule”for demonstration of efficacy for regulatory purposes; (iii) strengthen the collective commitment of nations, international organizations, potential donors and industry; (iv) stimulate public and/or private partnerships to invest in vaccine development and licensure; and (v) identify potential markets for an effective and safe CHIKF vaccine. |
format | Online Article Text |
id | pubmed-6336248 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Public Library of Science |
record_format | MEDLINE/PubMed |
spelling | pubmed-63362482019-01-31 Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development Rezza, Giovanni Weaver, Scott C. PLoS Negl Trop Dis Review Chikungunya fever (CHIKF) is an emerging infectious disease caused by an alphavirus transmitted by Aedes spp. mosquitoes. Because mosquito control programs are not highly efficient for outbreak containment, vaccines are essential to reduce the burden of disease. Although no licensed vaccine against CHIKF is yet available, many highly promising candidates are undergoing preclinical studies, and a few of them have been tested in human trials of phase 1 or 2. Here, we review recent findings regarding the need for a CHIKF vaccine and provide an update on vaccines nearing or having entered clinical trials. We also address needs to tackle bottlenecks to vaccine development—including scientific and financial barriers—and to accelerate the development of vaccines; several actions should be taken: (i) design efficacy trials to be conducted during the course of outbreaks; (ii) evaluate the opportunity for adopting the “animal rule”for demonstration of efficacy for regulatory purposes; (iii) strengthen the collective commitment of nations, international organizations, potential donors and industry; (iv) stimulate public and/or private partnerships to invest in vaccine development and licensure; and (v) identify potential markets for an effective and safe CHIKF vaccine. Public Library of Science 2019-01-17 /pmc/articles/PMC6336248/ /pubmed/30653504 http://dx.doi.org/10.1371/journal.pntd.0006919 Text en © 2019 Rezza, Weaver http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Rezza, Giovanni Weaver, Scott C. Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development |
title | Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development |
title_full | Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development |
title_fullStr | Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development |
title_full_unstemmed | Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development |
title_short | Chikungunya as a paradigm for emerging viral diseases: Evaluating disease impact and hurdles to vaccine development |
title_sort | chikungunya as a paradigm for emerging viral diseases: evaluating disease impact and hurdles to vaccine development |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6336248/ https://www.ncbi.nlm.nih.gov/pubmed/30653504 http://dx.doi.org/10.1371/journal.pntd.0006919 |
work_keys_str_mv | AT rezzagiovanni chikungunyaasaparadigmforemergingviraldiseasesevaluatingdiseaseimpactandhurdlestovaccinedevelopment AT weaverscottc chikungunyaasaparadigmforemergingviraldiseasesevaluatingdiseaseimpactandhurdlestovaccinedevelopment |